CJC-1295
Also known as
Long-acting synthetic GHRH analogue studied for lean mass and longevity. Preliminary evidence — unapproved, elevated risk; one registered trial found, no peer-reviewed human efficacy data available.
Evidence
Animal or in-vitro only
Risk band
Serious AEs reported or theoretical
Research goals
Summary
CJC-1295 is a long-acting growth-hormone-releasing hormone (GHRH) analog, but no peer-reviewed papers were provided for this entry, so no factual claims about its effects, efficacy, or safety can be substantiated from the source set. The signals reference a single registered trial, yet without accompanying published abstracts there is no usable human or preclinical evidence here to evaluate. On the basis of the available literature in this file, the therapeutic evidence cannot be assessed and should be treated as preliminary pending peer-reviewed data.
No indexed peer-reviewed sources for this entry yet.
For educational purposes only.